Showing results (1971-1980 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|July 22, 1999
Simultaneous exposure to interleukin-18 and interleukin-10 in vitro synergistically augments murine spleen natural killer cell activityM J Micallef, T Tanimoto, K Torigoe, et al.Cancer Immunology, Immunotherapy : CII|August 4, 1999
Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complexU Grohmann, M L Belladonna, R Bianchi, et al.Cancer Immunology, Immunotherapy : CII|August 4, 1999
Prerequisites for the immunotherapy of cancerG Pawelec, A Engel, M AdibzadehCancer Immunology, Immunotherapy : CII|July 22, 1999
Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivoT Kielian, E Nagai, A Ikubo, et al.Cancer Immunology, Immunotherapy : CII|July 22, 1999
The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosisJ Haux, A C Johnsen, B Steinkjer, et al.Cancer Immunology, Immunotherapy : CII|September 9, 1999
Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibodyD C Rice, A I Chapoval, L Porter, et al.Cancer Immunology, Immunotherapy : CII|September 4, 1999
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancerM Setti, D Bignardi, A Ballestrero, et al.Cancer Immunology, Immunotherapy : CII|September 4, 1999
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activityL L Worth, S F Jia, T An, et al.Cancer Immunology, Immunotherapy : CII|September 4, 1999
Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cellsP Jantscheff, R Herrmann, G Spagnoli, et al.Cancer Immunology, Immunotherapy : CII|September 29, 1999
Function and dysfunction of CD4(+) T cells in the immune response to melanomaW H Fischer, P thor Straten, P Terheyden, et al.Pageof 652